METERA PHARMACEUTICALS, INC.

Somerville, MA · Founded 2016 · Biotech · Defunct

MPX-111, an inhaled small-molecule remodeling kinase inhibitor targeting PDGFR/VEGFR/FGFR for idiopathic pulmonary fibrosis

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
Somerville, MA
Founded
2016
Latest Form D
$4.2M, Dec 2016
Total capital
$5.7M
Federal grants
$1.5M
1 award · 2020
Rank in peer group#171 of 326
Private capital raised
$4.2M
1 Form D · last Dec 2016
118 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20162017201820192020FEDERAL ↑EQUITY ↓Cumulative $5.7M$1.5M1st Form D$4.2M
20162017201820192020FEDERAL ↑EQUITY ↓Cumulative $5.7M$1.5M1st Form D$4.2M

Latest events

  • Federal grantHealth and Human S · Phase II · Inhaled IRK inhibitors as a novel therapeutic for IPF$1.5M
  • Private capital raisedForm D · SEC · 1st filing$4.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Avrum SpiraExecutive OfficerNamed in SEC Form D filings
  • Avrum Spira, M.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Marc LenburgExecutive Officer, DirectorNamed in SEC Form D filings
  • Marc Lenburg, Ph.D.Executive OfficerNamed in SEC Form D filings
  • Meredith C. Fisher, Ph.D.DirectorNamed in SEC Form D filings
  • Vijay MurthyDirectorNamed in SEC Form D filings
Show all 7 people
  • Vijay Murthy, Ph.D.DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .